NasdaqGM - Delayed Quote USD

Foghorn Therapeutics Inc. (FHTX)

5.49 +0.26 (+4.97%)
At close: April 26 at 4:00 PM EDT
5.49 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
34,155.00
34,155.00
19,228.00
1,319.00
430.00
Operating Expense
142,061.00
142,061.00
136,365.00
102,053.00
68,961.00
Operating Income
-107,906.00
-107,906.00
-117,137.00
-100,734.00
-68,531.00
Net Non Operating Interest Income Expense
10,875.00
10,875.00
5,675.00
-1,847.00
22.00
Other Income Expense
2,831.00
2,831.00
2,580.00
1,261.00
-291.00
Pretax Income
-94,200.00
-94,200.00
-108,882.00
-101,320.00
-68,800.00
Tax Provision
4,226.00
4,226.00
--
--
--
Net Income Common Stockholders
-98,426.00
-98,426.00
-108,882.00
-101,320.00
-68,800.00
Diluted NI Available to Com Stockholders
-98,426.00
-98,426.00
-108,882.00
-101,320.00
-68,800.00
Basic EPS
-2.34
--
-2.62
-2.73
-6.23
Diluted EPS
-2.34
--
-2.62
-2.73
-6.23
Basic Average Shares
41,974.48
--
41,591.43
37,171.15
11,046.80
Diluted Average Shares
41,974.48
--
41,591.43
37,171.15
11,046.80
Total Operating Income as Reported
-107,906.00
-107,906.00
-117,137.00
-100,734.00
-68,531.00
Total Expenses
142,061.00
142,061.00
136,365.00
102,053.00
68,961.00
Net Income from Continuing & Discontinued Operation
-98,426.00
-98,426.00
-108,882.00
-101,320.00
-68,800.00
Normalized Income
-98,426.00
-98,426.00
-108,882.00
-100,087.00
-68,509.00
Interest Income
10,875.00
10,875.00
5,675.00
59.00
1,001.00
Interest Expense
--
--
--
1,906.00
979.00
Net Interest Income
10,875.00
10,875.00
5,675.00
-1,847.00
22.00
EBIT
-107,906.00
-107,906.00
-117,137.00
-99,414.00
-67,821.00
EBITDA
-104,455.00
-104,455.00
-113,816.00
-96,187.00
-66,494.00
Reconciled Depreciation
3,451.00
3,451.00
3,321.00
3,227.00
1,327.00
Net Income from Continuing Operation Net Minority Interest
-98,426.00
-98,426.00
-108,882.00
-101,320.00
-68,800.00
Total Unusual Items Excluding Goodwill
--
--
--
-1,233.00
-291.00
Total Unusual Items
--
--
--
-1,233.00
-291.00
Normalized EBITDA
-104,455.00
-104,455.00
-113,816.00
-94,954.00
-66,203.00
Tax Rate for Calcs
0.00
0.00
--
--
--
12/31/2020 - 10/23/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

STTK Shattuck Labs, Inc.
10.59
+8.28%
 
LYEL Lyell Immunopharma, Inc.
2.1700
-1.36%
 
PRLD Prelude Therapeutics Incorporated
4.0700
+0.74%
 
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
 
ELVN Enliven Therapeutics, Inc.
17.18
+2.38%
 
ALXO ALX Oncology Holdings Inc.
16.86
-0.06%
 
BCAB BioAtla, Inc.
2.5400
+12.89%
 
NBTX Nanobiotix S.A.
5.74
-1.03%
 
AGIO Agios Pharmaceuticals, Inc.
31.49
-0.57%
 
PMVP PMV Pharmaceuticals, Inc.
1.7500
+2.34%